v3.19.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Total Revenue $ 101,713 $ 67,746 $ 197,290 $ 131,169
COST OF REVENUE 52,747 37,216 101,209 73,336
GROSS PROFIT 48,966 30,530 96,081 57,833
Operating expenses:        
General and administrative 29,577 20,983 61,719 38,050
Research and development 2,587 1,073 3,796 2,029
Sales and marketing 12,324 7,680 23,540 14,455
Total operating expenses 44,488 29,736 89,055 54,534
INCOME FROM OPERATIONS 4,478 794 7,026 3,299
Interest expense, net 1,304 1,407 3,130 2,892
Other (income) expense (10) 124 5,159 62
Loss on extinguishment of debt 1,018 0 1,018 0
Income (loss) before taxes 2,166 (737) (2,281) 345
Income tax expense (benefit) 175 (357) (1,848) 81
NET INCOME (LOSS) 1,991 (380) (433) 264
Deemed dividends on preferred stock and amortization of beneficial conversion feature 0 2,771 0 5,627
Gain on redemption of preferred stock 0 (9,075) 0 (9,075)
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS $ 1,991 $ 5,924 $ (433) $ 3,712
INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS        
Basic (in dollars per share) $ 0.02 $ 0.07 $ (0.00) $ 0.05
Diluted (in dollars per share) $ 0.02 $ 0.07 $ (0.00) $ 0.04
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic (in shares) 98,297 81,017 96,734 80,789
Diluted (in shares) 102,336 90,168 96,734 89,305
Clinical Services        
Total Revenue $ 88,982 $ 59,540 $ 175,192 $ 116,511
GROSS PROFIT 42,602 27,505 86,161 53,435
Pharma Services        
Total Revenue 12,731 8,206 22,098 14,658
GROSS PROFIT $ 6,364 $ 3,025 $ 9,920 $ 4,398

Source